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Identification of Gene Expression Changes Induced
by Chemical Allergens in Dendritic Cells:
Opportunities for Skin Sensitization Testing
Lucy A. Gildea1, Cindy A. Ryan1, Leslie M. Foertsch1, Jennifer M. Kennedy1, Rebecca J. Dearman2,
Ian Kimber2 and G. Frank Gerberick1
Cellular changes within resident skin dendritic cells (DCs) after allergen uptake and processing are critical
events in the acquisition of skin sensitization. Here we describe the development of a set of selection criteria to
derive a list of potential target genes from previous microarray analyses of human peripheral blood-derived
(peripheral blood mononuclear cells (PBMCs)-DCs) treated with dinitrobenzene sulfonic acid for predicting
skin-sensitizing chemicals. Based on those criteria, a probing evaluation of the target genes has been conducted
using an extended chemical data set, comprising five skin irritants and 11 contact allergens. PBMCs-DCs were
treated for 24 hours with various concentrations of chemicals and in each instance the expression of up to 60
genes was examined by real-time PCR analysis. Consistent allergen-induced changes in the expression of many
genes were observed and further prioritization of the targets was conducted by analysis of the same genes in
DCs treated with non-sensitizing chemicals to determine their specificity for skin sensitization. Real-time PCR
analyses of multiple chemical allergens, irritants, and non-sensitizers have identified 10 genes that demonstrate
reproducibly high levels of selectivity, specificity, and dynamic range consistent with providing the basis for
robust and sensitive alternative approaches for the identification of skin-sensitizing chemicals.
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INTRODUCTION
Langerhans cells (LCs) are considered to be the principle
antigen-presenting cell in the skin and they typify the sentinel
role of immature dendritic cells (DCs) as they are critical to
the development of allergic contact sensitization (Steinman
and Banchereau, 1998). Following exposure to a chemical
allergen, LCs effect antigen internalization, processing, and
presentation; processes that require their migration from the
epidermis to regional lymph nodes and maturation into
immunostimulatory DCs capable of presenting antigen
effectively to responsive T lymphocytes (reviewed by
Cumberbatch et al., 2000). Many biological changes occur
in LCs throughout this process including the alteration of
surface markers (Aiba and Katz, 1990; Schwarzenberger and
Udey, 1996; Verrier et al., 1999), the production of cytokines
(Enk and Katz, 1992; Wang et al., 2002), and the induction of
signal transduction pathways (Ku¨hn et al., 1998).
Expression profiling provides an opportunity to investigate
genome-wide changes induced in LCs or DCs following
encounter with allergen. This approach has been used by
others to study various biological responses in DCs and/or
LCs such as activation and differentiation (Richards et al.,
2002), tolerogenicity (Suciu-Foca Cortesini et al., 2001),
modulation by steroids (Griffin et al., 2004), and antimicro-
bial responses (Messmer et al, 2003; Semnani et al., 2003; Ju
and Zenke, 2004). Since few reports have focused on contact
allergy, we used transcript profiling to characterize responses
to chemical allergens in a type of LCs surrogate, human
peripheral blood-derived DCs (peripheral blood mononuc-
lear cells (PBMCs)-DCs). One important objective was to
identify significant gene changes that could be exploited for
the development of in vitro methods for identifying skin
sensitizing chemicals (Ryan et al., 2004). A number of genes
were examined and evaluated in detail for their reproduci-
bility using real-time PCR analysis. These genes have been
analyzed further in PBMCs-DCs after treatment with multiple
chemical allergens and irritants. Genes identified through this
approach that display measurable discriminatory capability
will provide new and exciting opportunities to develop novel
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alternative methods for the identification and characteriza-
tion of skin-sensitizing chemicals.
RESULTS
Selection of candidate genes
Microarray experiments conducted previously on dinitro-
benzenesulfonic acid (DNBS)-treated PBMCs-DCs-identified
genes that appeared related to the activation of DCs by a
contact allergen (Ryan et al., 2004). Although approximately
2,880 significant (Pp0.01) gene changes were observed, we
chose to consider for further analysis by PCR only those genes
that were regulated highly significantly (Pp0.001) by both
concentrations of DNBS tested (1 and 5 mM) to reduce the
potential selection of genes that were regulated as a result of
cellular cytotoxicity. Thus, we selected 60 genes from the
118 significant at Pp0.001 to validate further in another
DNBS experiment with PBMCs-DCs derived from a different
donor. Genes were originally selected from the microarray
data and later categorized by either their magnitude of altered
expression (largest fold change), presumed or confirmed
mechanistic association with skin sensitization or DCs
biology, immunologic function, cellular function, or baseline
constitutive expression (detectable by other methods).
The 60 selected genes were characterized by real-time
PCR in two additional DNBS experiments for further
evaluation as potential targets important to the regulation of
DCs activation by an allergen. These experiments were
performed with PBMCs-DCs derived from different donors to
address donor-to-donor variability and included multiple
concentrations of DNBS to allow definition of dose–response
relationships and to determine the dynamic range of gene
expression. Additionally, expression levels of at least 50 of
the 60 genes were examined in a larger experiment with
elutriated monocyte-derived immature DCs from a single
donor that were treated with three contact allergens, one skin
irritant, and one non-sensitizer. From these experiments the
potential gene list was reduced to 29 that could be analyzed
more quickly with a larger number of chemicals (data not
shown). Genes that showed altered expression following
treatment with the skin irritant (and therefore did not permit
discrimination between allergens and irritants), or failed to
display sufficiently substantial changes in expression follow-
ing exposure to chemical allergens were eliminated.
Evaluation by real-time PCR gene expression changes in
chemical-treated DCs
Expression of the 29 selected genes was analyzed by real-
time PCR using additional allergens and non-allergens. It is
well known that differences between contact allergens with
respect to their relative skin-sensitizing potency can span four
or more orders of magnitude (Basketter et al., 2000; Kimber
et al., 2003). Therefore, we evaluated chemicals that display
a range of sensitizing potencies (weak to extreme). The
potency categories used are those outlined by the European
Centre for Ecotoxicology and Toxicology of Chemicals that
are based on the results of the Local Lymph Node Assay in
the form of their EC3 values (ECETOC, 2003). Initially, DNBS
(the water soluble analog of the extreme contact allergen
2,4-dinitrochlorobenzene), a strong allergen (propyl gallate
(PLG)), a non-sensitizing skin irritant (benzoic acid (BA)),
and a non-sensitizer (benzene sulfonic acid (BsA)) were
tested in independent experiments. Extreme and strong
allergens were included to gauge the degree of altered
expression that was observed with these genes, and to
compare their expression levels with two different allergens
with similar potencies, while the irritant and non-sensitizer
were included also to determine selectivity of the genes.
Multiple doses of each chemical were tested to determine the
dynamic range of each gene, but the doses used maintained a
cell viability of 85% or greater as measured by propidium
iodide staining (data not shown). However, the highest dose
used in each experiment was intended to induce 10–15% cell
death in order to assess the impact of viability on expression
levels.
Owing to the limited number of PBMCs-DCs generated
from each leukoprep and the number of cells required to
obtain sufficient quantities of RNA to test in multiple
reactions, Table 1 depicts representative mean fold change
data for the 29 genes from independent experiments using
different donor cells for each experiment. Although the data
presented here illustrate results from one individual experi-
ment for each of the four chemicals, at least one additional
experiment using a different donor was conducted for each
chemical. DNBS treatment induced measurable changes in
expression compared with control for all genes analyzed, and
in most cases for all doses used, except for IL3RAX where
only the high dose was found to be effective. As expected, the
magnitude of alterations in expression varied between genes
as there was a 43.6-fold decrease in ABCA6 gene expression,
whereas only a 2.1-fold increase in the expression of TTRAP,
although which genes would be regulated more robustly was
not predicted. In all cases the direction of regulation
measured was the same as that observed in the microarray
study and confirms our initial findings with DNBS. The
magnitude of expression changes was generally slightly
greater by real-time PCR analysis compared with microarray
analysis. However, the fold-changes observed were compar-
able with changes identified in subsequent real-time experi-
ments using DNBS with some variation in the magnitude of
regulation between PCR reactions with particular genes as
mentioned above.
The strong allergen, PLG, also induced measurable
changes in a majority of the genes analyzed (Table 1) and
was analogous to DNBS treatment, although with some
exceptions. Unlike DNBS treatment, the level of expression
of CCRL2, RIT1, and IL3RAX in PLG-treated cells was
unaffected at all doses examined and only modest changes
were observed for TXN and TTRAP. Although the irritant BA
did not generate many changes in gene expression, the non-
sensitizer BsA, that is structurally similar to DNBS but lacks
the reactive moiety associated with skin sensitization, did
cause changes in the expression of a few genes such as G1P2,
IL3RAX, AK1RC2, S100A4, CD1E, and SPN but not to the
same degree as that induced by the allergens, DNBS and
PLG. Moreover, the fold changes observed with BsA
treatment for the CTSH and CCL2 genes (42-fold increase)
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were in a direction opposite of that seen with the allergenic
chemicals PLG and DNBS.
Scoring of regulated genes
To determine that a gene is associated strongly with DCs
activation by an allergen, we decided that it must be
regulated by multiple allergens (robust) and must be specific
for allergens and not irritants (selective). Therefore, to
prioritize the 29 genes of interest with respect to their
robustness and selectivity as well as to reduce the number of
candidate genes, the genes were scored according to their
expression level induced by additional allergens and irritants
bringing the total number of allergens evaluated to 11 and
irritants to four. The allergens used represented multiple
chemical classes (e.g., aldehydes, quinones) estimated to
follow different reaction mechanisms and varying potency
categories ranging from weak to extreme (ECETOC, 2003).
The weak allergens (eugenol (Eug), hydroxycitronellal (HC),
nickel sulfate (NiSO4), and penicillin g sodium salt,
Benzylpenicillin (PenG)), moderate allergens (hexylcinnamic
aldehyde (HCA) and, IsoEug), strong allergens (PLG, 3,4-
diethoxy-3-cyclobutene-1,2-dione (SADE), and HQ), and
extreme allergen diphenylcyclopropenone (DCP) and DNBS
(the water soluble analog of the extreme allergen DNCB)
were among those tested. The irritants tested were sodium
lauryl sulfate (SDS), BA, methyl salicylate, and salicylic acid
Table 1. Mean fold change of chemical-treated DCs versus control-treated DCs1
DNBS PLG BsA BA
Gene symbol 1.0 mM 2.5 mM 5.0 mM 100 lM 250 lM 500 lM 1.0 mM 5.0 mM 200 lM 400 lM 800 lM
ABCA6 5.2 18.6 43.6 ND 11.5 39.2 1.2 1.4 1.5 1.3 1.4
AKR1C2 15.9 42.9 229.2 8.0 10.1 15.5 1.7 2.1 1.3 1.3 1.7
ARHGDIB 2.2 5.1 7.0 2.0 3.4 19.6 1.0 1.2 2.2 1.4 2.0
BLNK 4.7 10.9 39.8 5.3 2.8 23.6 1.3 1.3 1.3 1.3 1.2
CCL2 1.5 1.8 53.8 1.7 2.0 1.2 2.8 1.4
CCL23 3.5 7.4 9.8 2.5 3.0 11.2 1.3 1.6 1.3 1.9 1.1
CCL4 3.4 2.8 17.5 2.2 2.8 3.9 2.3 1.1 1.5 1.2 1.2
CCRL2 4.6 7.2 5.2 1.4 1.5 1.5 1.1 1.1 1.3 1.1 1.1
CD1E 2.3 3.6 25.3 2.2 4.5 30.8 2.9 4.1 1.2 1.2 1.5
CTSH 4.8 5.0 5.1 1.6 2.1 4.2 2.2 2.5 2.4 1.4 1.6
CYP27A1 2.8 15.1 6.2 2.83 4.3 7.1 1.1 1.5 1.2 1.2 1.2
EPB41L2 6.2 6.3 8.3 2.6 6.6 15.3 1.1 1.3 1.2 1.1 1.1
FCER1A 3.4 4.5 10.7 3.7 4.7 23.9 1.1 1.1 1.4 1.1 1.1
FGL2 4.5 5.1 22.5 1.9 3.1 20.1 1.0 1.2 1.4 1.3 1.1
G1P2 3.5 6.9 11.9 1.2 1.1 4.7 3.0 2.8 1.2 1.4 1.4
HML2 12.7 36.3 42.2 2.7 3.2 18.1 1.0 1.3 1.6 1.2 1.6
IER3 7.3 4.3 2.5 1.87 2.5 5.5 1.5 1.8 1.2 1.2 1.1
IL3RAX 1.0 1.1 3.4 1.4 1.3 1.2 3.0 4.7 1.4 1.4 1.5
MRC1 1.4 2.3 6.5 1.1 1.8 3.8 1.4 1.4 1.1 1.4 1.3
NOTCH3 3.7 7.6 18.7 5.0 8.0 8.5 1.0 1.5 1.5 1.4 1.2
QPCT 2.2 2.1 3.3 1.6 2.3 4.8 1.2 1.2 1.0 1.2 1.1
RIT1 1.2 2.4 5.8 1.1 1.0 1.5 1.0 1.1 1.0 1.4 1.0
S100A4 12.7 36.3 42.2 1.9 3.9 97.5 1.8 2.6 1.6 1.7 2.0
SH3BP5 4.1 13.2 12.3 1.5 1.3 3.4 1.9 2.0 1.0 2.2 1.9
SLAM 9.6 7.3 15.6 ND 6.1 3.3 1.2 1.9 1.4 1.2 1.2
SPN 1.4 3.1 5.5 2.7 4.0 20.0 2.1 2.2 1.0 1.2 1.1
TRIM16 1.6 5.7 15.5 2.6 2.3 7.1 1.3 1.7 1.3 1.1 1.0
TTRAP 2.5 2.1 2.1 2.4 2.4 2.0 1.1 1.2 1.3 1.9 2.0
TXN 3.8 2.9 12.8 2.3 2.2 2.5 1.5 1.6 1.1 1.1 1.1
1Mean fold change was derived from real-time PCR reactions run on either replicate wells of a single sample or single wells of biological replicates for each
experiment. Each chemical was analyzed in separate experiments using different donor cells and the data are from a single experiment per chemical and are
representative of results observed in additional experiments.
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(SA). Several of these chemicals were tested in more than one
experiment and therefore have multiple data points for each
gene. However, due to limited number of RNA samples
obtained from certain experiments, not all genes were tested
with each chemical. Nevertheless, the information in Table 2
indicates how many chemicals a particular gene was tested
against, which chemical tested negative for the allergens and
positive for the irritants, and which chemicals were not tested
at all for that particular gene.
Scoring of fold changes listed in Table 2 was made by
determining a positive response for a gene in all chemicals
tested and the number of chemicals tested per gene. A
positive response was defined as being greater than a 2-fold
change in the direction identified originally in the initial
DNBS experiment at one of the doses tested. Since the
purpose of the analysis was to identify genes that were
capable of discriminating between allergens and irritants,
separation of allergens into specific potency categories was
Table 2. Scoring of candidate genes by positive and negative responses in real-time PCR reactions upon chemical
treatment1
Allergen scoring2
Allergen that tested
negative3
Allergen
not tested4 Irritant scoring5
Irritant that tested
positive6
Irritant
not tested7
Gene symbol (7*)
(no. positive/no.
tested)
(no. negative/no.
tested)
(no. positive/no.
tested)
(no. positive/no.
tested)
ABCA6* 11/11 1/4 SDS (1/3)
AKR1C2* 11/11 1/4 SDS (3/5)
ARHGDIB* 10/10 NiSO4 2/4 BA (2/2)
SA (1/2)
BLNK* 11/11 1/4 SA (1/1)
CCL2 8/10 DPC
Eug
HQ 1/3 BA (1/2) MS
CCL23* 11/11 1/4 SA (1/1)
CCL4* 10/11 HQ 0/4
CCRL2 4/9 DCP
HQ
PLG
HCA
Pen G
IsoEug
Eug
0/3 SA
CD1E 11/11 2/4 SDS (2/4)
BA (1/3)
CTSH 8/11 HQ
HCA
HC
0/4
CYP27A1* 11/11 1/4 SA (1/1)
EPB41L2 9/11 HC
Eug
1/4 SDS (1/4)
FCER1A 7/8 SADE NiSO4
Eug
IsoEug
0/3 SA
FGL2 10/11 DCP 0/4
G1P2 2/9 PLG
HC
SADE
NiSO4
Pen G
HCA
DCP
IsoEug
Eug
1/3 SDS (1/4) SA
HML2* 11/11 0/4
IER3 4/8 DCP
HQ
HCA
Pen G
IsoEug
Eug
NiSO4
1/3 BA (1/3) SA
Table 2 Continued on the following page
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not performed at this time and no associations with fold
change and a chemical’s potency were made at this time. In
addition, a gene was scored positive regardless of the number
of times it registered a positive in any experiment tested with
that particular chemical. For further clarity, Table 2 also lists
the number of times that a particular gene was tested and
registered as positive or negative for a chemical.
As shown in Table 2, several genes were affected by all of
the allergens tested such as AK1RC2, ARHGDIB, CCL23,
CD1E, CYP27A1, HML2, NOTCH3, S100A4, and signaling
lymphocytic activation molecule (SLAM). Other genes
(ABCA6, BLNK, CCL4, EPB41L2, TRIM16, and TTRAP)
showed an association with the majority of allergens tested.
Interestingly, it was usually the weak allergens that did not
Table 2. continued
Allergen scoring2
Allergen that tested
negative3
Allergen
not tested4 Irritant scoring5
Irritant that tested
positive6
Irritant
not tested7
Gene symbol (7*)
(no. positive/no.
tested)
(no. negative/no.
tested)
(no. positive/no.
tested)
(no. positive/no.
tested)
IL3RAX 5/8 DPC
PLG
SADE
IsoEug
Eug
PenG
1/4 SDS (1/2)
MRC1 5/11 HQ
HC
NiSO4
Eug
HCA
DCP
1/4 SDS (1/3)
NOTCH3* 11/11 1/4 SDS (1/5)
QPCT 6/10 DPC
HCA
HQ
NiSO4
IsoEug 1/3 SDS (1/2) SA
RIT1 5/9 NiSO4
HCA
DCP
PLG
IsoEug
Eug
0/4
S100A4* 6/6 HC
PenG
IsoEug
Eug
DCP
0/4
SH3BP5 7/9 Pen G
DCP
IsoEug
Eug
0/4
SLAM* 11/11 1/4 BA (1/2)
SPN 8/9 DCP IsoEug
Eug
1/3 BA (1/3) SA
TRIM16 9/11 NiSO4
Eug
1/4 SDS (1/4)
TTRAP 5/8 NiSO4
HCA
PenG
IsoEug
Eug
DCP
0/4
TXN 10/11 SADE 2/4 BA (1/3)
SDS (1/4)
1The expression of candidate genes in allergen-treated DC were analyzed in real-time PCR reactions and the mean fold change levels of expression for each
gene was measured and compared to the levels induced by irritant treatment.
2Allergen scoring was performed by recording the number of allergens in which a positive response was observed out of the number of allergens that
particular gene was tested. A positive response represents a fold change level that was larger than 2 for upregulated genes and 2 for downregulated genes.
A positive response was recorded regardless of the dose at which it registered positive or the number of times a positive response was observed.
3Lists the allergen to which no positive response was observed at any dose in any experiment.
4Some genes were not tested in all allergens mentioned in the table due to limited quantity of RNA thus the allergens not tested are listed.
5Irritant scoring describes the number of irritants in which a positive response was observed out of the number of allergens tested and a positive response is
the same as that described for allergen response.
6The irritant that tested positive at any dose analyzed is described. Parenthetic numbers indicate the number of experiments for which a positive response
was observed out of the number of times that particular gene was tested with that specific irritant.
7Genes that initially appear to have the most predictive potential for an alternative method (*).
www.jidonline.org 1817
LA Gildea et al.
Classification of Gene Panel Associated with Skin Sensitization
meet the 2-fold change criterion. The results of the scoring
also show that some genes are not strongly associated with
allergen activation such as CCRL2, G1P2, MRC1, and QPCT.
The specificity of the genes can be assessed by determining if
they are regulated by irritants. For example, CTSH, FCER1A,
HML2, or RIT1 were induced in only one irritant tested and in
only one out five independent experiments with that
particular chemical. It is important to note that even if genes
were regulated up or down by an irritant, the degree of
change could be considerably more robust with an allergen
as was the case with AKR1C2, for example the highest
concentration of SDS induced only a 2.6-fold change in
AKR1C2 whereas the allergen isoeugenol (IsoEug) induced a
17.2-fold change in expression (data not shown). As a result,
the data presented in Table 2 allows determination of which
genes are associated strongly with allergen activation of DCs
and which also show specificity for allergens versus irritants.
Comparison of gene expression for use as potency predictor
To determine whether any of 29 genes display potential for
categorization of relative sensitization potency as is currently
derived using the local lymph node assay (Basketter et al.,
1999; Kimber et al., 2003), the fold change levels of four
candidate genes were analyzed in separate experiments with
five chemicals from different potency categories ranging from
non-sensitizer to strong allergen. The data are from individual
PCR experiments for each chemical but are representative of
results obtained from multiple runs of a particular sample set
or from single PCR runs of multiple experiments per
chemical. As shown in Figure 1 all genes show differences
in expression upon treatment with chemicals from different
potency categories, but to a different degree. NOTCH3 and
SLAM display measurable differences between all potency
groups analyzed, whereas ABCA6 showed expression differ-
ences between the irritant and the weak and moderate
allergen but did not further separate the moderate and strong
allergen. Distinguishable levels of AK1RC2 expression were
observed between the irritant and the weak allergen but were
not noticeably different among the chemical allergens of
higher potency classification. Therefore, this gene might be
capable of separating the irritants from allergens without
potency classification.
DISCUSSION
The aim of this study was to identify genes in DCs that are
associated strongly with activation by contact allergens and
do so in a selective manner such that they might serve as end
points for an in vitro method to predict the skin sensitization
potential of an unknown chemical. Therefore, we focused on
transcriptional analysis by real-time PCR of genes identified
previously by the Affymetrix Genechips platform (Ryan
et al., 2004) to elucidate pathways in DCs that are involved in
‘‘immune recognition’’ or antigen uptake, and subsequent
cell activation, as well as to identify additional genes that are
associated with allergen treatment that might have not been
considered otherwise.
The evaluation of surface marker expression, cytokine
production, and other markers of DCs activation is not new to
the field of alternative in vitro approaches. Early work
identified IL-1b, CD86, major histocompatability complex
class II, and CD54 as candidate molecules (Enk and Katz,
1992; Degwert et al., 1997; Reutter et al., 1997; Pichowski
et al., 2000; Rougier et al., 2000; Staquet et al., 2004). While
these studies have provided possible new approaches, many
of those published have been confronted with some degree of
restriction (Kimber et al., 2001; Ryan et al., 2001). Recently,
Aeby et al. (2004) described results using IL-1b and aquaporin
P3 gene expression combined with flow cytometric analysis
of CD86-positive cells to characterize the sensitizing
potential of chemicals. While their data are promising,
additional allergens and irritants will need to be evaluated
to determine the ability of these markers to predict the skin
sensitization potential of unknown chemicals.
Owing to the variability reported in many of the surface
markers studied to date, it is appropriate to consider
alternative experimental strategies, including microarray
transcript profiling, that permit a more holistic interrogation
of genes and pathways that influence the ability of DCs to
initiate adaptive immune responses to chemical allergens.
Recently, we reported the phenotypic and functional changes
at the genomic scale in DCs treated with contact allergens
(Ryan et al., 2004). From this original data set we have sought
to identify novel markers to investigate for their mechanistic
relevance for contact allergy and their potential as effective
markers that could be exploited in the development of
alternative approaches for skin-sensitization testing.
We evaluated by real-time PCR analysis 60 out of 118
genes that were statistically significant in our original gene
profile at Pp0.001 (Ryan et al., 2004). The genes were
selected using several criteria such as expression level,
biological function and reproducibility as they were sig-
nificantly regulated similarly in subsequent experiments using
DNBS-treated PBMCs-DCs derived from different donors
(data not shown). Furthermore, experiments conducted with
cells from a single donor treated with six chemicals
demonstrated genes which appeared to be associated with
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Figure 1. Expression of candidate genes in chemical-treated DCs. PBMCs-
DCs were exposed to vehicle alone (either medium only or medium
containing 0.1% DMSO), 5 mM BsA, 175mM SDS, 12.5 mM PenG, 100 mM
HCA, and 500 mM PLG for 24 hours. Real-time PCR analysis after treatment
expressed as fold change of expression induced upon treatment compared to
control treated DCs. Each chemical represents an independent experiment
performed on separate occasions using different donor cells for each
experiment. Data are from an individual experiment for each chemical and
are representative of additional experiments.
1818 Journal of Investigative Dermatology (2006), Volume 126
LA Gildea et al.
Classification of Gene Panel Associated with Skin Sensitization
allergen-induced DCs activation. From those experiments, 29
candidate genes were analyzed further in subsequent
experiments that included a strong allergen, PLG, as well as
an irritant, BA, and a non-sensitizer, BsA. For the most part
similar responses were observed between the two allergens,
DNBS and PLG, for most of the genes examined with fewer
similarities being observed between the allergens and the
irritant or the non-sensitizer.
To investigate further the association of these 29 genes
with DCs activation by allergen, additional allergens, and
irritants were tested. In order to categorize these genes
initially, we separated the chemicals into two groups,
allergens and irritants, without consideration for potency.
As the amount of data generated at this point was sizeable,
this process allowed us to determine whether some genes
demonstrated little specificity with allergen activation of the
PBMCs-DCs. For this evaluation, objective parameters such
as presence or absence in a allergen/non-allergen, the dose to
which a response was registered, and the nature of the
chemical to which a response did not qualify were
considered and thus resulted in a group of 11 genes that
initially appear to be strongly associated with DCs activation
by allergens and thus serve as potential predictors of skin
sensitization (Table 2).
While we are hesitant to designate this as a priority
ranking at this time, many of these genes have been the most
robust and selective markers to date and therefore are the
most likely candidates. Notch receptors play a key role in
cellular processes including proliferation, differentiation, and
apoptosis. Mammals have four known Notch receptors
and Langerhans cells have been reported to constitutively
express Notch-3 and -4 (B. Nickloff, unpublished observa-
tions reported in Weijzen et al., 2002). In addition, Jagged-1,
a Notch ligand that is constitutively expressed at high levels
in kerationcytes, is reported to induce maturation of human
monocyte-derived DCs via Notch-1 signaling (Weijzen
et al., 2002). We have observed consistent upregulation
in message for Notch-3 in allergen-treated DCs versus
control.
SLAM was first identified on activated T and B cells.
Of late, SLAM signaling appears to be associated with
the induction of maturation (Bleharski et al., 2001; Kruse
et al., 2001), however, in a direction opposite of our
observations. We consistently observe SLAM downregulation
after 24 hours of treatment by both microarray and real-time
PCR analysis (Ryan et al., 2004) and further exploration may
reveal that these differences are due to the kinetics of DCs
activation.
BLNK or B-cell linker protein represents a central linker
protein that bridges the B-cell receptor-associated kinases
with a multitude of signaling pathways (Fu et al., 1998).
Linker or adapter proteins provide mechanisms by which
receptors can amplify and regulate downstream effector
proteins and BLNK has been shown to be critical in the
integration of signaling cascades downstream of immuno-
receptor tyrosine-based activation motif-bearing receptors.
While the specific function of BLNK in DCs has not been
elucidated, DCs do express immunoreceptor tyrosine-based
activation-containing receptors such as the Fc receptors
(Bonnerot et al., 1997; Kanazawa et al., 2003).
The membrane-associated protein encoded by ABCA6 is a
member of the superfamily of ATP-binding cassette transport-
ers which transport various molecules across extra- and
intracellular membranes. Although the exact function of this
gene is unknown it may play a role in macrophage lipid
homeostasis (Dean et al., 2001; Kaminski et al., 2001) and
conceivably function in either receptor-specific or passive
transport of molecules across DCs surfaces.
AKR1C1/C2 genes encode members of the aldo-keto
reductase family of proteins. These enzymes convert alde-
hydes and ketones to their corresponding alcohols using
nicotinamide adenine dinucleotide (reduced form) and/or
nicotinamide adenine dinucleotide as cofactors. Addition-
ally, they work to control ligand access to nuclear receptors
as part of a switch mechanism with short-chain dehydro-
genases/reductases (Bauman et al., 2004). Although these
proteins are 97.8% homologous and only differ in seven
amino acids (Shiraishi et al., 1998) their activities and
affinities for their steroid substrates are different (Couture
et al., 2003) and since the Affymetrix target sequence that we
used to design primer pairs contains the region of homology
between the two genes, we cannot speculate at this time as to
a role of either or both of these genes in DCs biology.
However, at this time only two reports have been published
on the expression of AKR1C1 in skin, a mouse study (Pelletier
et al., 2003) and a human study reporting expression in
abdominal subcutaneous and adipose tissue (Blouin et al.,
2005). No studies reporting DCs, LCs, or keratinocyte
expression of either AKR1C1 or AKR1C2 have been
published.
CCL4, also known as macrophage inflammatory protein-1
beta, is one of four members of the macrophage inflammatory
protein-1 CC chemokine subfamily. Chemokines are low
molecular weight cytokines that are produced by many cell
types and stimulate/regulate the movement of leukocytes
between blood and tissues by acting via G-protein-coupled
cell surface receptors (Maurer and von Stebut, 2004) and thus
make excellent candidates to study. In addition, Verheyen
et al. (2005) studied the response of CCL4, as well as CCL2,
CCL3, and CCL3L1, in CD34þ derived DCs following
treatment with contact allergens and irritants and observed
clear increases in expression with nickel, DNCB, oxazalone,
and Eug treatment.
Several of the analyzed genes have emerged as better
predictors of DCs activation and thus are more likely
candidates for a predictive model for skin sensitization.
The top genes that displayed the most promise based
on our selection criteria of fold-change levels induced in
individual experiments, the scoring results from Table 2 such
as the dose at which a positive response was recorded and
the number of times it tested positive is denoted with an
asterick in Table 2. However, this list is not intended to
diminish the potential for other genes of interest that are not
listed in this table to be used in future assay development or
to conclusively associate the genes listed in Table 2 with
predictive power.
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Data from four genes listed in Table 2 are shown in
Figure 1 and they all display measurable differences between
allergens and irritants/non-sensitizers. Although it is a bit
premature to determine which, if any genes are capable of
classifying allergens into specific potency categories, pre-
liminary data on Notch3, AKR1C2, ABCA6, and SLAM, as
well as other genes listed in Table 2, suggest that this is
feasible in addition to designating a compound as an allergen
or irritant. It also appears that some genes show good potential
to differentiate between an irritant and a non-sensitizer.
It is difficult, but important, to incorporate all of the
components involved in the induction of skin allergy into the
development of an alternative method. It is also important to
correctly choose the genes that should be investigated more
thoroughly and the number and nature of the chemicals to
which these genes should be validated against. In addition,
there is no standard chemical test set identified to evaluate
the utility of any new gene that shows predictive potential or
any fixed cellular criteria, such as viability and activation
state, determined. Therefore, it was the goal of this study to
identify a panel of candidate genes and evaluate them for
their potential against a large number of chemicals using
cytotoxicity restrictions. As any gene identified in this study
has been chosen for its robustness or specificity, it must be
examined in a larger-scale study with even more unique
chemicals. We envision the design of a model that
incorporates both a mechanistic understanding of the
immunobiology of skin sensitization and the results from
these gene expression profile studies. We do not anticipate
that any one gene will be capable of predicting skin
sensitization alone, but rather foresee a select panel of genes
to be used to phenotype the activity of a test chemical.
MATERIALS AND METHODS
Materials
DNBS (CAS-no. 885-62-1), PLG ( CAS-no 121-79-9), SADE (CAS-no
2892-51-5), HCA (85% purity; CAS-no 101-86-0), Eug (CAS-no 97-
53-0), NiSO4 (CAS-no 10101-97-0), SA (CAS-no 69-72-7), BsA
(CAS-no 98-11-3), BA ( CAS-no 65-85-0), IsoEug (CAS-no 97-54-1)
and DCP (CAS-no 886-38-4) were purchased from Aldrich,
Milwaukee, WI. HC (CAS-no 107-75-5), HQ (CAS-no 123-31-9),
PenG (CAS-no 61-33-6), and methyl salicylate (CAS-no 119-36-8)
were purchased from Sigma, St Louis, MO. SDS (10% solution; CAS-
no 151-21-3) was purchased from Invitrogen Inc. (Carlsbad, CA). All
chemicals used, except for HCA, were at least 95% pure and
concentration was calculated using w:v. HCA (85% pure) dose
solutions were prepared taking purity into account.
Culture medium
Complete culture medium consists of RPMI-1640 containing 1X
L-glutamine supplemented with 1X penicillin–streptomycin antibiotic
mixture (GIBCO, Rockville, MD), 30 mM 2-mercaptoethanol (GIB-
CO), and 10% heat-inactivated fetal bovine serum (Hyclone
Laboratories, Logan, UT). For DCs generation, complete culture
medium was supplemented with 10 ng/ml granulocyte-macrophage
colony-stimulating factor (R&D Systems, Minneapolis, MN) and
10 ng/ml IL-4 (R&D Systems) referred below as cytokine-containing
medium.
Generation of peripheral blood-derived DCs
Enriched human leukocyte preparations were purchased from Sera-
Tec Biologicals (North Brunswick, NJ) and were received as
numerically coded units with no identifiable information. As such
this study was conducted in accordance with the Declaration of
Helsinki Principles. Following dilution with an equal part of
complete medium the leukocytes were separated over Ficoll-Paque
gradient (Amersham Pharmacia Biotech, Uppsala, Sweden). The
PBMCs fraction was collected, washed, and counted using a Coulter
Counter (Beckman-Coulter Inc., Miami, FL). The PBMCs concentra-
tion was adjusted to 5 106 cells/ml with complete medium and
30 ml of the cell suspension was plated in T75 flasks. Following
2 hours incubation at 371C/5% CO2, the non-adherent cells were
removed. Of cytokine-containing medium, 10 ml was added to the
remaining adherent cells in the flask. The cultures were incubated at
371C/5% CO2 for 48 hours during which the adherent cells became
loosely or non-adherent. On day 2, the cells were collected,
centrifuged, resuspended to a concentration of 1 106 cells/ml in
fresh cytokine-containing medium and re-plated. On day 5, residual
T cells and B cells were removed from the cultures using two
passages over CD2 (pan T cell) and CD19 (pan B cell) immuno-
magnetic beads (Dynal, Oslo, Norway) according to the
manufacturer’s directions. Following depletion of T- and B cells,
the remaining DCs were resuspended to concentration of 1 106
cells/ml in fresh cytokine-containing medium and re-plated in a T75
culture flask. The cultures were incubated for another 48 hours
before experimental use. As previously described (Hulette et al.,
2002), DCs cultured for a total of 7 days in this manner express an
immature DCs phenotype: HLA-DRþ , CD1aþ , CD83, CD80lo, and
CD86lo (data not shown). Alternatively, DCs were derived
from elutriated human monocytes (Advanced Biotechnology Inc.,
Columbia, MD) that were cultured in the same manner as the
PBMCs. The phenotype of these elutriated monocyte-derived
immature DCs at day 7 was found to be identical to that of the
DCs cultured from the enriched human leukocyte preparations (data
not shown).
Chemical treatment of DCs
Day 7 PBMCs-DCs or elutriated monocyte-derived immature DCs
were collected, washed in complete medium and resuspended in
cytokine-containing medium. In all, 2 106 cells were plated in
each well of a six-well culture plate (Falcon; Becton Dickinson
Labware, Franklin Lakes, NJ). The test chemical dosing solution or
vehicle control was added to the cells (final volume 3 ml/well) and
the cultures were incubated for 24 hours at 371C/5% CO2.
Chemicals were initially dissolved in either complete medium or
100% DMSO and subsequent dilutions were performed in
cytokine-containing media. Vehicle-treated PBMCs-DCs (either
cytokine-containing medium or 0.1% DMSO in cytokine-containing
medium) were used as controls. Either single or replicate wells were
plated for each control and chemical treatment cultures. Final in-
well concentrations of chemicals were chosen by the amount of
cytotoxicity that it induced in DCs. PBMCs-DCs viability following
chemical treatment was assessed by propidium iodide dye exclusion
using a Coulter Epicss XL flow cytometer (Beckman Coulter, Miami,
FL). The viability of the control PBMCs-DCs ranged from 95 to 99%
while exposure to higher chemical concentrations were slightly
cytotoxic, resulting in DCs viability ranging from 85 to 95%. Any
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chemical concentration that induced more than 15% cytotoxicity
was excluded from further analysis.
RNA isolation and cDNA generation
Total RNA was isolated from after 24 hours of incubation using
TRIzols Reagent (GIBCO). Pellet PaintTM NF (Novagen, Madison,
WI) was used as a co-precipitant to aid in the recovery of the RNA.
The resulting total RNA was purified further using RNeasy Mini Kit
(Qiagen, Valencia, CA) and the RNA content was determined
spectrophotometrically. Reverse transcription of RNA was performed
using the Omniscript RT kit (Qiagen). In all reactions, cDNA was
synthesized in 20ml using 1.5 mg of total human RNA from DCs and
10 mM Oligo-dt primers (Ambion Inc., Austin, TX). All reactions
contained 10 U of RNase Out RNAse inhibitor (Invitrogen) and the
resulting cDNA was diluted to 10 ng/ml with sterile PCR-grade water
and stored frozen (201C) until assayed.
Real-time PCR analysis
Quantitative PCR amplification of gene-specific cDNA’s was per-
formed in 96-well PCR plates with the iCycler thermal cycler and the
iCycler iQTM Real-Time PCR Detection System (Bio-Rad, Hercules,
CA). An equivalent of 50 ng of total RNA was used in 25ml of
QuantiTect SYBR Green PCR Master Mix (Qiagen). The real-time PCR
reaction mixture included 5ml of sample, forward and reverse primers
specific for each gene (0.3mM each), and the PCR master mix
containing probe (2 stock). The specific primer pair for each gene
was designed using either the Genbank sequence or the Affymetric
target sequence used for the U95A chips. The 96-well real-time PCR
format included seven, 10-fold dilutions of a PCR-purified DNA
standard (2 102 to 2 108 ng), a PCR negative control (minus
template), and up to 12 genes independently analyzed per plate. The
positive control and PCR standard was a rat intestinal calcium binding
protein PCR product that was gel purified away from the primers. Test
samples analyzed were either biological triplicates performed
individually within a given PCR run or single biological samples
performed in duplicate within a PCR run. In all experiments donor-
specific vehicle-treated controls were included for comparison.
Analysis of real-time PCR data
Optical real-time PCR data was analyzed using the default and
variable parameters available in the software provided with the
iCycler iQTM Real-Time PCR Detection System. The PCR threshold
cycle number (CT) and starting quantity of test RNA samples was
calculated after PCR baseline subtraction and CT determination had
been carried out on the standards. Standard curve equations were
calculated by regression analysis of the log of the copy number
(starting quantity) versus threshold cycle. The standard curve
equations (R2 usually 40.96) were used to calculate quantities of
test RNA. The mean relative fluorescence units were calculated
using individual well readings within a given PCR run on biological
samples and then converted to mean fold change comparing mean
relative fluorescence units of control samples versus mean relative
fluorescence units of treated samples. For each gene described in
Table 1, the data for each chemical presented represent either the
combined mean fold change from multiple PCR reactions (2–4)
within a single run or are the mean of fold changes calculated from
single real-time reverse transcriptase-PCR reactions run on each of
three replicate cultures from a single donor for any given chemical
within an experiment. Although each chemical represents a single
donor, each chemical was tested individually in independent
experiments.
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